IMR Press / FBL / Special Issues / cancer_metabolicgenes

The Impact of Metabolic Gene Signature with Respect to Tumor Prognosis, Microenvironment, and Immunotherapy

Submission deadline: 31 January 2024
Special Issue Editors
  • Jian Song, PhD
    Institute of Physiological Chemistry and Pathobiochemistry, University of Muenster, Munster, Germany
    Interests: tumour biology; vascular biology and immunology
  • Xueli Zhang, PhD
    State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China
    Interests: leukocyte transmigration in inflammation; extracellular matrix in autoimmune disease and gastrointestinal tumors; mechanisms of different immune cells involved in tumor microenvironment
Special Issue Information

Dear Colleagues,

Cancer is the leading cause of death worldwide and shortens life expectancy. The current pathological staging of tumors is of great value in predicting prognosis, but given the high morbidity and mortality of cancer, there is an urgent need for novel biomarkers that can predict prognosis against tumors and immunotherapy. Over the past decades, multiple tumor biomarkers have been validated and are now widely used in the clinic and proven to be effective. In recent years, with the emergence of iron death, copper death and disulfide death, new insights into the impact of metabolic genes on tumorigenesis, progression and treatment have been achieved and are considered as new directions for tumor therapy. The development of high-throughput sequencing technologies in proteomics and genomics has made it possible to study metabolic gene markers. The identification of metabolic gene markers is crucial for the development of therapeutic targets for precision immuno-oncology, which will also have a profound impact in the field of personalized medicine. The aim of this special issue is to bring together original research and review articles with a focus on tumor prognosis, identification of novel metabolic genes for immunotherapy, with an emphasis on immunotherapy.

Dr. Jian Song and Dr. Xueli Zhang
Guest Editors

Keywords
metabolic gene markers
immunotherapy
cancer
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (2 Papers)
Back to top